BLM

RecQ-like DNA helicase BLM · P54132 · BLM on Sugi Atlas →

824,610 patent compounds predicted against BLM, 599,406 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Aclarubicin (SCHEMBL4532)	0.67	10/20
Aclarubicin (SCHEMBL4533)	0.67	10/20
Daunorubicin (SCHEMBL3041)	1.00	9/20
Daunorubicin (SCHEMBL4444)	1.00	9/20
Daunorubicin (SCHEMBL4445)	1.00	9/20
Carubicin (SCHEMBL4201)	0.98	9/20
Idarubicin (SCHEMBL4838)	0.98	9/20
Detorubicin (SCHEMBL8642)	0.81	9/20
Rodorubicin (SCHEMBL8693)	0.54	9/20
Epirubicin (SCHEMBL3165)	1.00	8/20
Doxorubicin (SCHEMBL3242)	1.00	8/20
Doxorubicin (SCHEMBL3243)	1.00	8/20
Idarubicin (SCHEMBL3750)	1.00	8/20
Epirubicin (SCHEMBL8582)	1.00	8/20
Carubicin (SCHEMBL9552)	1.00	8/20
Zorubicin (SCHEMBL4023)	0.80	8/20
Zorubicin (SCHEMBL4024)	0.80	8/20
Zorubicin (SCHEMBL8231)	0.79	8/20
Zorubicin (SCHEMBL8232)	0.79	8/20
Amrubicin (SCHEMBL9140)	0.57	8/20

Clinical trials — most relevant to BLM by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations	PHASE2	COMPLETED
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy	PHASE2	RECRUITING
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	PHASE2	COMPLETED
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)	PHASE2	COMPLETED
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects	PHASE2	COMPLETED
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Niraparib and Dostarlimab in HRD Solid Tumors	PHASE2	UNKNOWN
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation	PHASE2	RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	PHASE1	RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	PHASE1	COMPLETED
Biological Significance of the Bloom's Syndrome Protein	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations	nan	RECRUITING
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	nan	RECRUITING
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Studying Biomarkers in Patients With Pancreatic Cancer	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BLM binder may also engage these)

Protein	Name	Similarity
Q9DEY9	—	1.000	Q9DEY9 →
Q9FT70	—	0.998	Q9FT70 →
O88700	—	0.997	O88700 →
Q05935	—	0.995	Q05935 →
Q5RJX8	—	0.995	Q5RJX8 →
Q6NTJ3	—	0.994	Q6NTJ3 →
Q24595	—	0.994	Q24595 →
Q94CU5	—	0.994	Q94CU5 →
F4JZ68	—	0.994	F4JZ68 →
Q6GX84	—	0.994	Q6GX84 →
Q7ZXG4	—	0.994	Q7ZXG4 →
Q8C0P0	—	0.993	Q8C0P0 →
Q6KAQ7	—	0.993	Q6KAQ7 →
Q9SB51	—	0.993	Q9SB51 →
A0JMT0	—	0.992	A0JMT0 →
Q949U2	—	0.992	Q949U2 →
P62289	—	0.992	P62289 →
B4GT53	—	0.992	B4GT53 →
Q9HCH5	—	0.992	Q9HCH5 →
A0A1S4GMU2	—	0.992	A0A1S4GMU2 →
P62290	—	0.992	P62290 →
Q90Z80	—	0.991	Q90Z80 →
A4IHT0	—	0.991	A4IHT0 →
P01103	—	0.991	P01103 →
A2ARZ3	—	0.991	A2ARZ3 →
Q6IVY4	—	0.991	Q6IVY4 →
Q8BN78	—	0.991	Q8BN78 →
P52551	—	0.991	P52551 →
Q8BYH8	—	0.991	Q8BYH8 →
Q9FY74	—	0.991	Q9FY74 →